Hostname: page-component-77c89778f8-m8s7h Total loading time: 0 Render date: 2024-07-20T23:10:42.827Z Has data issue: false hasContentIssue false
  • English
  • Français

Other Approaches to the Prevention of Aspergillosis

Published online by Cambridge University Press:  02 January 2015

David C.E. Speller
David C.E. Speller*
Affiliation:
Bristol Royal Infirmary, Bristol, England
*
Bristol Royal Infirmary, Marlborough Street, Bristol BS2 8HW, England
Get access Rights & Permissions [Opens in a new window]

Extract

Disseminated aspergillosis in the compromised host is an important and intractable problem in Great Britain, having a general incidence, when post-mortem data are included, approaching that quoted for the United States. It emerges as a most important cause of death in units where prolonged granulocytopenia accompanies treatment.

Rhame has presented a persuasive account of the environmental origin of aspergillus infection and the possibility of its control by environmental measures. This is an important issue for those involved in the planning of new units, for the use of protective isolation is under criticism as failing to provide significant benefit, and even general provision of filtered air to the unit may be beyond the budget allowed. We have to consider the minimum necessary measures to reduce the risk. Providing HEPA-filtered air to the unit may not be sufficient in itself; British heart transplant patients have died of aspergillosis (A. fumigatus), in some cases initiated soon after surgery, despite nursing in rooms with filtered ventilation (Newsom SWB, personal communication); and respiratory ventilators have been suspected as one source within such a unit. We also have to consider other approaches to the problem. Is there an endogenous element in the production of aspergillosis? Is there any prospect of successful chemoprophylaxis?

Type
Research Article
Information
Infection Control & Hospital Epidemiology , Volume 7 , supplement S2: Proceedings of the Second ICI/Stuart Workshop , February 1986 , pp. 125 - 127
Copyright
Copyright © The Society for Healthcare Epidemiology of America 1986

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Warren, RE, in Towse, G (ed). The Role of Intravenous Miconazole in the Treatment of Systemic Mycoses, Royal Society of Medicine International Symposium Series No 45. London, Academic Press, 1980, p 25.Google Scholar
2.Rogers, TR: Prevention of infection in neutropenic bone marrow transplant patients. Antibiot Chemother 1985; 33:90.CrossRefGoogle ScholarPubMed
3.Armstrong, D: Protected environments are discomforting and expensive and do not offer meaningful protection. Am J Med 1984; 76:685.CrossRefGoogle Scholar
4.Warren, RE, Warnock, DW: Clinical manifestations and management of aspergillosis in the compromised host, in Warnock, DW. Richardson, MD (eds). Fungal Infection in the Compromised Patient Chichester, John Wiley & Sons Ltd, 1982, pp 119–153.Google Scholar
5.Kahanpaa, A: Bronchopulmonary occurrence of fungi in adults especially according to cultivation material. Acta Pathol Microbiol Immunol Scand[B] 1972; Supplement 227:1.Google Scholar
6.Stammberger, H, Jakse, R, Beaufort, F: Aspergillosis of the paranasal sinuses. Ann Olol Rhinol Laryngol 1984; 93:251.Google Scholar
7.Gerson, SL, Talbot, GH, Hurwitz, S, et al: Prolonged granulocytopenia: The major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. Ann Intern Med 1984; 100:345.Google Scholar
8.Berkow, RL, Weisman, SJ, Provisor, AJ, et al: Invasive aspergillosis of paranasal tissues in children with malignancies. J Pediatr 1983; 103:49.CrossRefGoogle ScholarPubMed
9.Trull, AK, Parker, J, Warren, RE: IgG enzyme-linked immunosorbent assay for diagnosis of invasive aspergillosis: A retrospective study of over 15 years of transplant recipients. J Clin Pathol, 1985; 38:1045.Google Scholar
10.Meunier-Carpentier, F: Chemoprophylaxis of fungal infections. Am J Med 1984; 76:652.CrossRefGoogle ScholarPubMed
11.Meunier-Carpentier, F, Snoeck, R, Gerahi, J, et al: Amphotericin B nasal spray as prophylaxis against aspergillosis in patients with neutropenia. N Engl J Med 1984; 311:1056.Google Scholar
12.Espinel-Ingrof, A, Shadomy, S, Gebhart, RJ: In vitro studies with R 51211. Antimicrob Agents Chemother 1984; 26:5.Google Scholar
13.Odds, FC, Webster, CE, Abbott, AB: Antifungal relative inhibition factors: BAY 1-9139, bifonazole, butoconazole. isoconazole. itraconazole (R51211), oxiconazole, Ro 14-4767/002. sulconazole, terconazole and vibunazole (BAY n-7133) compared in vitro with nine established antifungal agents. J Antimicrob Chemother 1984; 14:105.Google Scholar
14.Van Cutsem, J, Van Gerven, F, Van de Ven, MA, et al: Itraconazole, a new triazole (hat is orally active in aspergillosis. Antimicrob Agents Chemother 1984; 26:527.Google Scholar
15.Troke, PF, Andrews, RJ, Marriott, MS, et al: In vivo activity of U K-49,858 against opportunistic fungal pathogens. Proceedings of the IXth international Congress of Human and Animal Mycology 1985, abstract R2-7.Google Scholar